Blanket Purchase Agreement 36F79719D0160-36E79724A0023
Award Date
7/26/24
Last Date to Order
7/25/26
Federal Agency
National Acquisition Center
Awardee
Catalyst Pharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The key products and services being delivered under this federal contract IDV award are the pharmaceutical drug Firdapse (amifampridine) provided by prime contractor Catalyst Pharmaceuticals, Inc. Catalyst has been awarded a $5,500,000 Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) National Acquisition Center to supply Firdapse, an FDA-approved treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. This BPA was placed against Catalyst's...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
The provided information describes a Blanket Purchase Agreement (BPA) contract vehicle awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Amylyx Pharmaceuticals Inc., a self-certified small disadvantaged business. The single-award BPA, valued at $50,000, enables VA facilities nationwide to order the pharmaceutical product RELYVRIO through June 2024. RELYVRIO, containing the active ingredients sodium phenylbutyrate and taurursodiol, is indicated for the...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Fera Pharmaceuticals, LLC, a woman-owned small business. The BPA, valued at up to $255,000, is for the procurement of Phospholine Iodide, a pharmaceutical drug. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and allows the VA and other agencies to efficiently and compliantly acquire the needed pharmaceutical product from Fera...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...
The subject federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a division of the U.S. Department of Veterans Affairs (VA), to Amylyx Pharmaceuticals Inc. (Amylyx). The BPA, valued at $50,000, is for the procurement of RELYVRIO, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS) developed by Amylyx. As a self-certified small disadvantaged business, Amylyx has established several contract vehicles with the VA to facilitate the...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Recordati Rare Diseases Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The single-award BPA has a ceiling value of $3,156,115 and a period of performance from July 2021 to July 2026. The BPA is for the procurement of specialized pharmaceutical products, including Signifor, Carbaglu, Cystadane, Isturisa, and Cystadrops. These medications are used to...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Alexion Pharmaceuticals Inc., a foreign-owned, for-profit biopharmaceutical company. The BPA, valued at $4,239,517.80, has a period of performance from September 1, 2022, through August 31, 2026. The primary purpose of this BPA is to provide the pharmaceutical drug Strensiq, used to treat the rare genetic disorder perinatal/infantile- and juvenile-onset...